T-cell clones that react against autologous human tumors
- PMID: 2146210
- DOI: 10.1111/j.1600-065x.1990.tb00803.x
T-cell clones that react against autologous human tumors
Abstract
T cells (derived from peripheral blood lymphocytes [PBL], lymph nodes or tumor tissues and restimulated with autologous tumor cells and expanded in interleukin-2 [IL-2]), when cloned, produce three functional classes of clone. Class I T-cell clones exhibit the phenotype of alpha/beta cytotoxic T lymphocytes (CD3+, CD8+, CD4-, WT31+), use their CD3-alpha/beta complexes for cognate function, and lyse the autologous tumor cells specifically in a major histocompatibility complex (MHC) Class I-restricted manner. The second class of T cell clone expresses identical phenotype but exhibits a rather broad cytotoxic profile against the autologous and allogeneic tumor cells derived from tumors with similar and/or dissimilar histologies. Although these CTL clones can, at times, show MHC Class I-restricted killing and use their T-cell receptors (TCR) complexes for function, activation via certain accessory molecules, particularly lymphocyte-function associated (LFA-1) antigens, might induce their broad cytotoxic behavior. The nature of the tumor antigen recognized by the Class I antigen-specific CTL clones remains unknown. It is evident, however, that more than one antigen can be associated with a given tumor and they are recognized by different CTL clones from individual patients. The third class of T-cell clone is usually of CD4+ alpha/beta T cells (CD3+, CD4+, CD8-, WT31) and these T-cell clones exhibit no cytotoxicity toward the autologous or allogeneic target cells. When tested for potential regulatory property, one type of CD4+ T-cell clone exhibits the characteristics of helper T cells. This type induces or amplifies cytotoxic response in fresh PBL by elaborating interleukin-2 (IL-2) and interferon-gamma). These helper T-cell clones can proliferate against the autologous tumor cells and demonstrate functional specificity for the autologous tumor cells. The other type of CD4+ T-cell clone exhibits the phenotype of the helper T-cell clone (CD3+, CD4+, CD8-, WT31+) but suppresses the cytotoxic response of the autologous PBL in co-culture in the presence of the autologous tumor cells and exogenous IL-2. In some situations, these CD4+ suppressor T-cell clones exhibit considerable specificity for the autologous tumor cells. They do not suppress the cytotoxic response against allogeneic targets or against EBV-infected autologous lymphoblastoid cells. Furthermore, they specifically up-regulate their IL-2 receptors (IL-2R) when stimulated by the autologous tumor cells or with autologous tumor cell-pulsed antigen-presenting cells.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma.J Exp Med. 1989 Jun 1;169(6):1961-76. doi: 10.1084/jem.169.6.1961. J Exp Med. 1989. PMID: 2471770 Free PMC article.
-
Selective expansion of a specific anti-tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements.Eur J Immunol. 1990 Apr;20(4):825-31. doi: 10.1002/eji.1830200417. Eur J Immunol. 1990. PMID: 1971794
-
Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.Cancer. 1994 Aug 15;74(4):1275-82. doi: 10.1002/1097-0142(19940815)74:4<1275::aid-cncr2820740416>3.0.co;2-q. Cancer. 1994. PMID: 7914469
-
Interplay between the TCR/CD3 complex and CD4 or CD8 in the activation of cytotoxic T lymphocytes.Immunol Rev. 1989 Jun;109:119-41. doi: 10.1111/j.1600-065x.1989.tb00022.x. Immunol Rev. 1989. PMID: 2527803 Review.
-
Suppression of immune responses by cloned T cells and their products.Behring Inst Mitt. 1992 Apr;(91):78-86. Behring Inst Mitt. 1992. PMID: 1388020 Review.
Cited by
-
Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin.Cancer Immunol Immunother. 1991;33(6):411-6. doi: 10.1007/BF01741603. Cancer Immunol Immunother. 1991. PMID: 1878894 Free PMC article.
-
Regulatory T cells and tumor immunity.Cancer Immunol Immunother. 2005 Dec;54(12):1153-61. doi: 10.1007/s00262-005-0699-9. Epub 2005 May 3. Cancer Immunol Immunother. 2005. PMID: 15868167 Free PMC article. Review.
-
Manipulation of regulatory T cells and antigen-specific cytotoxic T lymphocyte-based tumour immunotherapy.Immunology. 2015 Feb;144(2):186-96. doi: 10.1111/imm.12387. Immunology. 2015. PMID: 25243729 Free PMC article. Review.
-
Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA.J Clin Invest. 1993 Feb;91(2):684-92. doi: 10.1172/JCI116249. J Clin Invest. 1993. PMID: 8432869 Free PMC article.
-
Clonal analysis of in vivo activated CD8+ cytotoxic T lymphocytes from a melanoma patient responsive to active specific immunotherapy.Cancer Immunol Immunother. 1993 Jul;37(1):15-25. doi: 10.1007/BF01516937. Cancer Immunol Immunother. 1993. PMID: 8513449 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials